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ABSTRACT 
Viral hepatitis, an inflammatory liver disease, is caused by various genotypes of hepatitis C viruses (HCV). 
Hepatitis C slowly sprouts into fibrosis, which progresses to cirrhosis. Over a prolonged period of time compen-
sated cirrhosis can advance to decompensated cirrhosis culminating in hepatic failure and death. Conventional 
treatment of HCV involves the administration of interferons. However, association of interferon with the ad-
verse drug reactions led to the development of novel anti-HCV drugs given as monotherapy or in combination 
with the other drugs. Advances in drug delivery systems (DDS) improved the pharmacokinetic profile and sta-
bility of drugs, ameliorated tissue damages on extravasation and increased the targeting of affected sites. Lipo-
somes and lipid based vehicles have been employed with polyethylene glycol (PEG) so as to stabilize the formu-
lations as PEG drug complex. Sofosbuvir, a novel anti-HCV drug, is administered as monotherapy or in combi-
nation with daclatasvir, ledipasivir, protease inhibitors, ribavirin and interferon for the treatment of HCV geno-
types 1, 2 and 3. These drug combinations are highly effective in eradicating the interferon resistance, recurrent 
HCV infection in liver transplant, concurrent HIV infection and preventing interferon related adverse effects. 
Further investigations to improve drug targeting and identification of new drug targets are highly warranted due 
to the rapid emergence of drug resistance in HCV. 
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INTRODUCTION 
Hepatitis C is an inflammatory disease of 
the liver that is often caused by various 
genotypes of HCV. Hepatitis B virus (HBV) 
and HCV infections affect 350 and 160 mil-
lion people worldwide respectively. Infec-
tion with HCV and HBV are more common 
in low and middle income countries (Liaw 
and Chu, 2009). Unavailability of the vac-
cine for HCV prophylaxis makes it harder to 
prevent the spread of infection in masses. 
The inability to reproduce HCV life cycle in-
vitro and occurrence of HCV in different 
genotypes are the major reasons behind the 
failure to produce anti-HCV vaccine. How-
ever, treatment of HCV infection involves 
the administration of different drugs over a 
prolonged period of time (Lindenbach et al., 
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2005). Major types of viral hepatitis, their 
causative agents, symptoms of exposure, in-
cubation periods, transmission and diagnos-
tic tests are depicted in Table 1.  
Chronic hepatitis C is a potentially pro-
gressive disease. It is characterized by the 
gradual development of hepatic damage to 
fibrosis and progression to cirrhosis 
(Schuppan and Afdhal, 2008). Compensated 
cirrhosis can progress to decompensated cir-
rhosis over a prolonged period, culminating 
into hepatic failure and death. Hepatocellular 
carcinoma (HCC) is the foremost cause of 
mortality in HCV infected patients (El-
Serag, 2012). HCC occurs predominantly in 
cirrhotic patients. However, several studies 
advocate the appearance of HCC in patients 
with bridging fibrosis without definite cir-
rhosis (Lok et al., 2009). 
Chronic HCV infection is a major cause 
of chronic liver disease and its associated 
deaths all over the world. Currently available 
highly active anti-HCV therapy eradicates 
the virus in 60 percent cases. Anti-HCV 
therapy also reduces the progression of he-
patic damage to cirrhosis. There is an up-
surge in mortalities worldwide due to the de-
layed detection, diagnosis and treatment of 
HCV infections. Transmission of HCV 
mainly occurs through the contact with blood 
and blood products in contrast to other hepa-
titis viruses (Alter and Klein, 2008). The 
foremost cause of its transmission is the 
sharing of non-sterilized needles and syring-
es. However, transfusion-related hepatitis C 
has almost vanished with the advent of rou-
tine blood screening for HCV antibodies in 
1991. Intravenous drug abuse is the most 
common risk factor now. Patients with high-
risk sexual behavior are also at higher risk of 
HCV infection which may be due to its asso-
ciation with herpes simplex type-2 infection 
(Tohme and Holmberg, 2010). 
 
Structure and life cycle of HCV 
HCV is a spherical virus. It contains its 
genetic information in the form of a single 
stranded RNA (Henke et al., 2008). Design-
ing new drugs for the treatment of HCV in-
fection requires understanding the life cycle 
of HCV (Scheel and Rice, 2013). RNA is an 
easier to process form of genetic information 
as compared to DNA as there is no need for 
transcription. It reduces the need for special-
ized viral enzymes, which facilitate the tran-
scription process. Other enzymes necessary 
for the synthesis of proteins are present in 
HCV. RNA of HCV is more prone to 
 
Table 1: Features of different types of viral hepatitis 
Disease Pathogen Symptoms Incubation 
period 
Method of 
transmission 
Diagnostic 
test 
Hepatitis A HAV,  
Picornaviridae 
Fever, 
headache, 
malaise, 
jaundice 
2-6 weeks Ingestion IgM  
antibodies 
Hepatitis B HBV, 
Hepadnaviri-
dae 
Severe liver dam-
age, chronic dis-
ease occurs 
3-26 weeks Parenteral, 
sexual  
contact 
IgM  
antibodies 
Hepatitis C HCV,  
Flaviviridae 
Same as HBV,  
more chronic 
2-33 weeks Parenteral PCR of viral 
RNA 
Hepatitis D HDV,  
Deltaviridae 
Severe liver dam-
age, high mortality 
rate 
6-26 weeks Parenteral, 
when co-
infected with 
HBV 
IgM  
antibodies 
Hepatitis E HEV,  
Caliciviridae 
Pregnant women 
may be at high risk 
and show high 
mortality, not 
chronic disease 
2-6 weeks Ingestion IgM  
antibodies, 
PCR of viral 
RNA 
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damage. It is advantageous to HCV as it al-
lows facile mutations (Helle and Dubuisson, 
2007). This continuous alteration in RNA 
makes it harder for the human hosts to de-
velop active or passive immunity against 
HCV (Scheel and Rice, 2013). HCV con-
tains a core in the form of RNA and a pro-
tein rich envelope which encloses the inner 
structure. Two envelope proteins, E1 and E2, 
allow the virus to attach to the liver cells 
(Bartosch et al., 2003). E1 protein has cer-
tain regions which are easily mutated and 
therefore makes it harder for the immunity to 
develop. There are six major HCV geno-
types, some of which are more common in 
certain regions and not frequently seen in 
other areas (Scheel and Rice, 2013). Geno-
type 1 is the most common genotype world-
wide and causes severe liver damage. HCV 
genotype 1 is also a major risk factor for 
hepatocellular carcinoma (Davidson et al., 
1995; Smith et al., 2014; Messina et al., 
2015). Occurrence of various genotypes of 
HCV hinders not only the development of 
new vaccines but also affects the selection of 
alternative treatment strategies and may con-
tribute to recurrent hepatic disease and post-
transplant cirrhosis (Prieto et al., 1999). Ta-
ble 2 shows different genotypes of HCV and 
their subtypes (Messina et al., 2015). Im-
portant steps involved in the life cycle of 
HCV include attachment, entry and uncoat-
ing of the virus with the host cell membrane, 
translation and poly-protein processing, rep-
lication, assembly, egress and release of the 
viral RNA. The host cell cofactors which 
contribute to the HCV infection in tissue cul-
ture system include polypyrimidine tract 
binding protein 1 (PTBP1), Dead box RNA 
helicase (DDX3), Heat Shock Protein 70 
(HSP70), Activating transcription factor 6 
(ATF6), alpha Actinin 1 (ACTN1), Scaven-
ger Receptor class B type I (SR-BI), Vesi-
cle-associated membrane protein A and B 
(VAP-A/B), Microsomal transfer protein 
(MTP), Phosphoinositide-3-kinase (PI3K) 
(Georgel et al., 2010). 
 
Pathophysiology of chronic hepatitis C 
Chronic hepatitis C is not the conse-
quence of direct destruction of hepatic cells 
by HCV. Rather, it results from an interme-
diate immune response that is large enough 
to encourage hepatic cellular injury. Such 
immune response is inadequate to eradicate 
the virus from its reservoir and culminates in 
fibrosis and hepatic cirrhosis. Quantitatively, 
HCV specific CD4 and CD8 T-cell respons-
es are weaker in the chronic phase than the 
acute phase of infection. Patients with the 
poor response in acute phase are often 
asymptomatic (no jaundice) and are more 
likely to become chronic carriers than those 
exhibiting high immune response (Grebely 
et al., 2011). HCV specific CD8 cells have 
an impaired effector function (both the se-
cretion of antiviral cytokines and lytic activi-
ty). The effectiveness of a combination of 
interferon and ribavirin is probably ex-
plained by its antiviral activity and restora-
tion of HCV specific immune response.  
 
 
Table 2: Genotypes of HCV with different subtypes and their global distribution  
Genotype  Subtypes Global distribution 
Genotype 1 1a,1b,1c,1e,1g,1h,1i Europe, Asia Pacific, North America, 
Latin America 
Genotype 2 2a,2b,2c,2d,2e,2i,2j,2k,2m,2q,2r, Europe, Asia Pacific 
Genotype 3 3a,3b,3g,3h,3i,3k Europe, South East Asia, Australia 
Genotype 4 4a,4b,4c,4d,4f,4g,4k,4l,4m,4n,4o,4p,4q,
4r,4t,4v,4w 
South Africa, Egypt 
Genotype 5 5a Australia, South Africa, USA 
Genotype 6 6a,6b,6c,6d,6e,6f,6g,6h,6i,6j,6k,6l,6m,6
n,6o,6p,6q,6r,6s,6t,6u,6v,6w,6xa 
Asia Pacific 
Genotype 7 7a Central Africa 
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Therapeutic targets for treatment of HCV 
infection 
Entry of viral RNA in the liver cells can 
be blocked through entry inhibitors which 
include neutralizing anti-receptor antibodies 
and receptor antagonists (Iwamoto et al., 
2014). Immune modulators include interfer-
on derivatives, TLR agonists, cytokines, and 
therapeutic vaccines (Yang et al., 2011). 
Helicase inhibitors block the subgenomic 
replication of virus (Najda-Bernatowicz et 
al., 2010). RNA interference is a technique 
in which small RNAs are used to alter the 
gene expression for the treatment of chronic 
hepatitis C and include drugs such as siRNA 
antisense oligonucleotides and miRNA 122 
antagonists (Castanotto and Rossi, 2009). 
Anti-HIV drugs such as protease inhibitors 
have also shown high potential to treat 
chronic hepatitis C (D’Avolio et al., 2013). 
Sofosbuvir, a polymerase inhibitor, is a 
highly effective anti-HCV drug (Pawlotsky, 
2014). Cyclophilin inhibitors suppress the 
replication of HCV and include cyclosporin 
A (Chatterji et al., 2015). Potential treatment 
of chronic hepatitis C may also involve 
drugs which target glycosylation through 
inhibition of alpha-glucosidase (Dwek et al., 
2002). Ribavirin, a guanosine analogue, is a 
prodrug and it blocks RNA synthesis 
(Hoofnagle, 2002). 
 
PHARMACEUTICAL INTERVEN-
TIONS FOR THE IMPROVEMENT OF 
ANTI-HCV THERAPY 
Advances in drug delivery systems 
(DDS) significantly improved the pharma-
ceutical issues associated with the use of an-
tiviral therapy related conventional DDS. 
Advanced DDS involve particulate carriers 
comprised of the lipid polymers. Advanced 
DDS improved the pharmacokinetic profile 
and stability of drugs, tissue damages on ex-
travasation and drug targeting of the affect 
sites (Table 3). Advanced DDS comprising 
liposomes and lipid based formulations are 
designed in such a way that more stabilized 
PEG drug complex is formed by linking 
PEG with interferons (Allen and Cullis, 
2004). 
Classical liposomes also known as 1st 
generation liposomes exhibit several limita-
tions related to the variability in pharmaco-
kinetics of anti-HCV drugs. Serum proteins 
affect the drug entrapment in classical lipo-
somes. Incorporation of cholesterol resolved 
this problem in such a way that it entrapped 
the drug contents and reduced the leakage of 
drug. The rapid clearance of drugs from 1st 
generation liposomes was also problematic. 
Uptake of these liposomes by mononuclear 
phagocytes in the liver and spleen results in 
exacerbation of site specific toxicity and de-
crease in drug distribution to other tissues. 
Increasing the half-life of circulating lipo-
somes resolved this issue as mononuclear 
phagocytes were blocked (Kumari et al., 
2010). Triggered release of the liposomal 
DDS allows anti-HCV drugs to reach target 
sites and improves therapeutic outcomes. 
There are two types of triggers for the re-
lease of drug from liposomal DDS (Allen 
and Cullis, 2013). Heat, ultrasound and light 
may act as remote triggers for the release of 
liposomal DDS, whereas local triggers in-
clude enzymes and pH changes.  
Development of nanoparticles improves 
drug targeting, increases efficacy and pre-
vents the adverse effects of anti-HCV drugs 
and the drugs used against HCV induced 
cancer. Nanoparticles are taken up by the 
liver, spleen and reticuloendothelial system. 
The particles having diameters 100 nm or 
less are highly accessible to the targeted site. 
Nanoparticles exhibiting hydrophobicity are 
taken up by the liver, whereas those showing 
lipophilicity are taken up by the spleen and 
reticuloendothelial system (Zhou et al., 
2011). Drugs used against HCV induced 
cancer are designed so as to increase the 
permeability and retention at the target site, 
inhibiting angiogenesis and targeting tumor 
vasculature (Brannon-Peppas and Blan-
chette, 2012). 
FDA has approved two recombinant al-
pha interferons as initial therapy for chronic 
hepatitis C. It was recommended in 1991 
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that three million units (MU) of interferon 
alfa-2b could be given three times per week 
for a period of 6 months (McHutchison et 
al., 2009). The use of 3 MU of interferon 
alpha-2a was also approved in 1996, for 
subcutaneous administration three times per 
week for a period of 12 months. Other drugs 
investigated for the treatment of HCV infec-
tion included interferon alpha-n1, consensus 
interferon, leukocyte-derived interferon and 
several beta interferons. However, the stand-
ardization and evaluation of comparative 
biological potency of various interferons re-
main problematic. 
 
 
Table 3: Pharmaceutical interventions for improving safety and efficacy of anti-HCV drugs 
Problems Conventional 
drug delivery 
system 
Advances drug  
delivery system 
Example of  
intervention 
References 
Degradation 
of interferon 
Degradation by 
metabolism, 
shorter half life, 
rapid renal clear-
ance, production 
of antibodies 
Pegylation to prevent 
degradation, immu-
nogenicity and in-
creasing half life 
Increase in the stabil-
ity of Interferon al-
pha2a through 
pegylation  
Liu et al., 
2006; 
Harris and 
Chess, 2003; 
Veronese 
and Pasut, 
2005 
Poor stability Reduced incorpo-
ration of hydro-
phobic drug in 
aqueous medium 
Liposomes provide 
the hydrophilic and 
hydrophobic envi-
ronment for incorpo-
ration of drugs 
Increase in the stabil-
ity of interferon with 
liposomes followed by 
pegylation  
Milla et al., 
2012 
Tissue dam-
ages on ex-
travasation of 
drugs 
Inadvertent ex-
travasations of 
toxic drugs causes 
tissue damages 
Advanced DDS re-
duces the tissue 
damages by extra-
vasation due to slow 
drug release  
Formulation of ribavi-
rin containing lipo-
somes to prevent 
hemolysis 
Guo et al., 
2015 
Poor bio-
distribution 
The drug widely 
distributes so that 
it causes damage 
to unrelated tis-
sues 
In controlled release 
DDS, the drug re-
leases slowly so that 
volume of drug distri-
bution is lowered 
which reduces side 
effects 
Biodegradable  
microspheres of  
interferons to in-
crease the efficacy 
and dose related  
adverse effects  
Sánchez et 
al., 2003 
Rapid  
clearance 
Rapid clearance 
of drugs through 
kidney necessi-
tates administra-
tion of high dose 
or continuous in-
fusion 
In advanced DDS, 
the clearance of the 
drug is decreased 
altering the pharma-
cokinetics of drug 
Pegylation, attach-
ment of dextran or 
crosslinking of pro-
teins decreases 
clearance of interfer-
on 
Sheffield, 
2001 
Lack of target 
tissue selec-
tivity 
The drug is widely 
distributed so that 
the concentration 
of drug is low at 
the target site re-
sulting in reduced 
therapeutic effect 
In advanced DDS, 
the concentration of 
the drug is high at 
the target site 
Increased liver target-
ing of ribavirin with 
niosomes. Nanoparti-
cle formulations of 
ribavirin can be used 
for viral infections in 
the brain. Surface of 
nano-carriers is modi-
fied so as to increase 
the delivery of ri-
tonavir to cells 
Hashim et 
al., 2010; 
Gaillard et 
al., 2014; 
Gunaseelan 
et al., 2010 
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PHARMACOLOGICAL INTERVEN-
TIONS FOR THE IMPROVEMENT OF 
ANTI-HCV THERAPY 
A combination of interferon and ribavirin 
has been used extensively against HCV in-
fections of genotype 2 and 3 which is highly 
correlated with the antiviral response in most 
patients. However, interferon therapy is as-
sociated with severe adverse reactions such 
as fatigue, anxiety, depression, hair loss and 
thrombocytopenia. Moreover, interferon is 
contraindicated in patients with hepatic de-
composition, auto-immune diseases and 
some psychiatric illnesses (Bull et al., 2009; 
Yamane et al., 2008). These factors prompt-
ed the investigation for novel anti-HCV 
drugs. 
 
Sofosbuvir  
Sofosbuvir is an oral, direct acting nucle-
otide analogue inhibitor of the nonstructural 
HCV protein NS5B polymerase (Pawlotsky, 
2013; Herbst and Reddy, 2013). Sofosbuvir 
was investigated as a substitute for interfer-
on. Sofosbuvir was concurrently adminis-
tered with ribavirin for the assessment of 
safety and efficacy in patient with HCV ge-
notype 2 and 3. It was found that sofosbuvir 
prevented the recurrence of HCV infection 
when used in combination with ribavirin 
(Curry et al., 2015). The dose of sofosbuvir 
used in HCV infection is 400 mg, whereas 
the dose of ribavirin depends upon the body 
weight. Ribavirin is administered as 
1000 mg per day when the body weight is 
less than 75 kg. The dose of ribavirin is in-
creased to 1200 mg per day for body weight 
of 75 kg or more. Sofosbuvir and ribavirin 
are highly effective in HCV genotype 2. 
However, this combination is less effective 
in HCV genotype 3 and the patients with liv-
er cirrhosis than HCV genotype 2 (Osinusi et 
al., 2013).  
Sofosbuvir and ribavirin combination 
therapy is more effective and safe alternative 
because it reduces the level of circulating 
RNA beyond the quantification limit. Sofos-
buvir associated adverse reactions include 
insomnia, fatigue, rashes and anemia. These 
adverse reactions were similar in patient with 
or without liver cirrhosis (Lawitz et al., 
2014; Jacobson et al., 2013). Sofosbuvir is 
also very effective in patients with liver 
transplant suffering from recurrent HCV in-
fections (Berenguer, 2015). 
 
Combination of sofosbuvir and ribavirin 
Various studies demonstrate that a com-
bination of sofosbuvir and ribavirin is the 
most effective treatment of HCV infection 
(Zeuzem et al., 2014; Gane et al., 2013). An 
important investigation involved the previ-
ously treated and untreated patient with HCV 
genotype 1, 2 and 3. The patients with HCV 
genotype 2 and 3 infection treated with 
sofosbuvir and ribavirin exhibited undetecta-
ble levels of viral RNA. The patients receiv-
ing the pegylated interferon along with 
sofosbuvir and ribavirin had sustained viro-
logic response. The inclusion of interferon in 
therapy had no significant effect on the viro-
logic response. Sofosbuvir monotherapy ex-
hibited a detectable level of the viral RNA in 
patients with genotype 2 and 3. The mono-
therapy with sofosbuvir also reduced the lev-
el of the hemoglobin (Neri et al., 2010; 
Lawitz et al., 2013). A combination of 
sofosbuvir and ribavirin inflicted urethral 
injury in previously untreated patients with 
HCV genotype 1 (Gane et al., 2013). Patients 
with HCV genotype 3 infections demonstrat-
ed the symptoms of angina pectoris after the 
treatment with sofosbuvir, ribavirin and in-
terferon (Kattakuzhy et al., 2015). 
 
Combination of sofosbuvir and ledipasivir  
Interferons cause various adverse reac-
tions such as hemolytic anemia, fatigue, pru-
ritus and rashes. Exclusion of interferons and 
ribavirin from HCV therapy is expected to 
reduce these adverse effects. Ledipasivir in-
hibits nonstructural protein NS5A while 
sofosbuvir inhibits a nonstructural protein 
NS5B present in HCV (Gane et al., 2014). 
Ledipasivir is highly active against HCV 
genotype 1a and 1b, whereas sofosbuvir is 
active against genotype 1 (Sulkowski et al., 
2014). The combination of ledipasivir and 
sofosbuvir with or without ribavirin exhibit-
ed highly sustained virologic response 
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among the patients with HCV genotype 1. A 
combination of ledipasivir and sofosbuvir 
was found to be more effective in patients 
with HCV genotype 1 than a combination of 
ledipasivir, sofosbuvir and ribavirin. The pa-
tients treated with ledipasivir and sofosbuvir 
exhibit some common adverse reactions such 
as fatigue, headache, insomnia and nausea 
however, patients treated with ledipasivir, 
sofosbuvir and ribavirin showed an upsurge 
of adverse effects such as fatigue, asthenia, 
cough, anemia and rashes (Zeuzem et al., 
2014). 
 
Combination of sofosbuvir and daclatasvir 
All oral combination therapy is desirable 
for patients with chronic HCV infection 
(Poordad et al., 2013). Daclatasvir  is an 
HCV NS5A replication complex inhibitor 
(Guedj et al., 2013). A combination of 
daclatasvir and sofosbuvir with or without 
ribavirin was investigated in patients infect-
ed with HCV genotype 1, 2, or 3. Both the 
drugs are the potent anti-HCV drugs and 
have broad genotypic coverage. Daclatasvir 
and sofosbuvir exhibited a sustained antiviral 
response in patients with HCV genotype 1a, 
1b and 3 who had shown poor response to 
previous treatment with telaprevir and bo-
ceprevir. The most common side effects of 
this combination include the fatigue, nausea, 
gastroenteritis, colitis and stroke. 
 
Combination of ribavirin with ritonavir, 
ombitasvir and dasabuvir  
Ombitasvir is an inhibitor of the NS5A. 
Ritonavir is a protease inhibitor and a potent 
inhibitor of CYP-450 so that it augments the 
response of other drugs (Kempf et al., 2007). 
Combination therapy of ritonavir with om-
bitasvir, dasabuvir and ribavirin has been 
investigated in previously treated and treat-
ment naive patients of HCV genotype 1 in-
fection and HCV infected cirrhotic patients. 
It was found that there was a high virologic 
response to treatment in the HCV genotype 1 
patients. Minor adverse effects appeared in 
those patients and did not allow any discon-
tinuation of therapy. There was also no drug 
resistance (Andreone et al., 2014). The ad-
verse effects occurring in those patients in-
cluded nausea, insomnia, purities and asthe-
nia. This favorable adverse effect profile ad-
vocates the oral use of protease inhibitors 
with or without interferon and ribavirin. It is 
also found that the multi-targeted regimens 
were highly effective in patient with HCV 
genotype 1 exhibiting no cirrhosis. 
 
Combination of sofosbuvir and daclatasvir 
therapy for liver transplant 
Hepatitis is a leading cause of liver 
transplant (Wong et al., 2015). Pegylated in-
terferon and ribavirin has been used in liver 
transplant recipients. However, severe ad-
verse effects and low antiviral activity are 
the major limitations of treatment with 
pegylated interferon and ribavirin 
(Xirouchakis et al., 2008). Protease inhibi-
tors, such as boceprevir and telaprevir have 
been investigated for recurrent HCV in liver 
transplant. These drugs had a moderate anti-
viral response when given in combination 
with interferon and ribavirin. However, use 
of strong inhibitors of CYP3A4 such as pro-
tease inhibitors resulted in serious drug-drug 
interactions. The study demonstrated that a 
regimen comprising sofosbuvir and daclatas-
vir was highly effective in liver transplant 
patients. Safety and efficacy profile of this 
regimen makes it the most appropriate treat-
ment option for liver transplant patient with 
recurrent HCV infection (Fontona et al., 
2013). 
 
Combination of sofosbuvir and daclatasvir 
for HCV in patients co-infected with HIV 
Pegylated interferon and ribavirin may 
not exhibit high virologic response in HCV 
patients co-infected with HIV (Carrat et al., 
2004). A combination of daclatasvir and 
sofosbuvir was investigated in these patients. 
Daclatasvir, an inhibitor of the NS5A and 
sofosbuvir, an inhibitor of NS5B, were given 
in combination to attain high virologic re-
sponse in patients with HCV genotype 1, 2 
and 3. The investigation showed that 
daclatasvir and sofosbuvir had a highly sus-
tained virologic response in HCV patients 
co-infected with HIV-1 genotypes 1, 2, 3 and 
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4. This combination had a lower virologic 
response in patients with HCV genotype 3 
with cirrhosis than the non-cirrhotic patients. 
The common side effects associated this reg-
imen were fatigue, headache and nausea 
(Smith et al., 2015). 
 
Combination of sofosbuvir and ribavirin for 
HCV in patients co-infected with HIV 
Interferon based regimens are still an im-
portant choice in patients with HCV geno-
types 1 or 4 co-infected with HIV. Interfer-
on-free regimens approved for patients with 
HCV genotype 2 or 3 co-infected with HIV 
include a combination of sofosbuvir and ri-
bavirin. Severe toxic effects and drug inter-
actions with anti-retroviral therapy limit the 
clinical usefulness of these regimens. An 
oral combination of sofosbuvir and ribavirin 
were investigated in patients with HCV co-
infected with HIV. Sofosbuvir and ribavirin 
achieved highly sustained virological re-
sponse after 12 weeks of treatment. These 
findings suggest that administration of 
sofosbuvir and ribavirin for 12 or 24 weeks 
is highly effective in chronic hepatitis C pa-
tients co-infected with HIV genotypes 1-4 
(Molina et al., 2015). 
 
CONCLUSION 
It can be concluded that the use of inter-
feron in the treatment of chronic hepatitis C 
exhibits a large number of adverse effects. 
Pegylation of interferon increases the effica-
cy and ameliorates the adverse effects of in-
terferons. Interferon can be replaced with 
nonstructural polymerase NS5A and NS5B 
inhibitors such as sofosbuvir and daclatasvir 
respectively. Sofosbuvir used as monothera-
py or in combination with ribavirin, 
daclatasvir and ledipasivir is highly effective 
in interferon resistance, recurrent HCV in-
fections in liver transplant and preventing 
interferon related adverse effects. Emergence 
of resistance to existing anti-HCV therapy 
and their adverse effects warrant further in-
vestigations in dosage form development. It 
is necessary to increase the efficacy of anti-
HCV drugs through active or passive target-
ing and the development of novel drugs to 
remediate this global calamity. 
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